Acorda Therapeutics (ACOR)  rumor spreaders are out in force. They are misleading the uninformed investors about a statement Biogen  (BIIB) just made at a conference.

We have taken partial profits on Acorda  at $30.20.

Our highest short tranche in Acorda  is from $33.48.

The rumor related to Biogen  buying Acorda  is proven false.   However, we are exiting Acorda with profit at $31.16 in the interest of defensive trading.  

 With this cover, we will exit the position completely.

If there are new actionable signals on Acorda, we will provide those in real-time to subscribers.  

30 day free trial subscriptions are available.

FREE: SUBSCRIBE TO ‘GENERATE WEALTH’ NEWSLETTER